)

Futura Medical (FUM) investor relations material
Futura Medical H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Interim CEO appointed in August 2025, launching a strategic and performance review to address underperformance, cost structure, and leadership succession.
H1 2025 saw launches in up to 25 countries, but consumer uptake and repeat sales were significantly below expectations, especially in the US and Europe.
Strategic review underway, focusing on cost-cutting, operational efficiency, and exploring options such as licensing, divestments, asset sales, and new partnerships.
New product development (Eroxon Intense, WSD4000) continues, with regulatory milestones targeted for late 2025 and launches expected from 2026 onward.
Financial highlights
H1 2025 revenue was £1.0–£1.01 million, with about half from US royalties and half from EU/UK sales; minor contributions from LATAM and Middle East.
Gross profit was £0.7–£0.73 million before a £0.49 million inventory obsolescence provision; gross profit after provision was £0.243 million.
Exceptional charges totaled £3.6–£4.05 million, mainly for impairment of plant/equipment and inventory write-downs.
Loss after tax was £6.59–£6.6 million; adjusted loss after tax (excluding exceptional and non-cash items) was £1.9–£2.0 million.
Cash at period end was £3.69 million, falling to £2.7–£2.71 million by end of August 2025, providing runway into January 2026.
Full year 2025 revenue now expected between £1.3–£1.4 million, well below initial forecasts.
Outlook and guidance
FY 2025 performance and revenue expected to be significantly below market expectations.
Cash runway extends into January 2026; further extension depends on commercial or financing actions.
Strategic review results and business update expected by end of Q1 2026.
Regulatory approval for Project Intense targeted by end of 2025, earliest launch in Q3/Q4 2026; WSD4000 launch anticipated in latter half of 2028.
US patent milestone payment delayed to H1 2026, impacting cash flow.
Next Futura Medical earnings date

Next Futura Medical earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage